Since IDH mutations are present in only 5% of de novo GBM while its occurrence increases to 95% in secondary GBM (129), targeting IDH-induced metabolic alteration might open new therapeutic avenues, at least in secondary GBM. The gene discussed is IDH2; the disease is glioblastoma.